HAL (France)open access
Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm
Real-world data, Bispecific antibodies, LYSA, Comparative effectiveness, Glofitamab, External control, Diffuse large B-cell lymphoma, CAR T-cell therapy
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 1000660
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.